Price T Rowe Associates Inc Verve Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 40,114 shares of VERV stock, worth $182,518. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,114

Previous 29,314 36.84%

Holding current value

$182,518

Previous $144,000 35.42%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.4 - $7.86 $47,520 - $84,888	10,800 Added 36.84%	40,114 $195,000
Q2 2024 Aug 14, 2024	BUY	$4.76 - $12.79 $18,792 - $50,494	3,948 Added 15.56%	29,314 $144,000
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $60,536 - $100,576	5,600 Added 28.33%	25,366 $337,000
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $12,782 - $27,040	1,446 Added 7.89%	19,766 $276,000
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $16,524 - $30,126	1,447 Added 8.58%	18,320 $243,000
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $19,209 - $28,655	1,440 Added 9.33%	16,873 $317,000
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $8,980 - $15,078	628 Added 4.24%	15,433 $223,000
Q4 2022 Feb 14, 2023	SELL	$17.85 - $40.7 $8,032 - $18,315	-450 Reduced 2.95%	14,805 $286,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $238,435 - $632,929	15,255 New	15,255 $525,000
Q1 2022 May 16, 2022	SELL	$20.92 - $39.36 $124,871 - $234,939	-5,969 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $190,649 - $327,220	5,969 New	5,969 $220,000
Q3 2021 Nov 15, 2021	SELL	$46.0 - $73.99 $31.5 Million - $50.7 Million	-685,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $21.9 Million - $41.3 Million	685,000 New	685,000 $41.3 Million

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $273M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Verve Therapeutics, Inc. Transaction History